The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Recombinant viral vector-based medicinal preparations.
However, not all innovations are equal and nor do they follow a constant upward trend. Instead, their evolution takes the form of an S-shaped curve that reflects their typical lifecycle from early emergence to accelerating adoption, before finally stabilising and reaching maturity.
Identifying where a particular innovation is on this journey, especially those that are in the emerging and accelerating stages, is essential for understanding their current level of adoption and the likely future trajectory and impact they will have.
110 innovations will shape the pharmaceutical industry
According to GlobalData’s Technology Foresights, which plots the S-curve for the pharmaceutical industry using innovation intensity models built on over 756,000 patents, there are 110 innovation areas that will shape the future of the industry.
Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry.
Innovation S-curve for the pharmaceutical industry
Recombinant viral vector-based medicinal preparations is a key innovation area in the pharmaceutical industry
Recombinant viral vectors are efficient vehicles with the ability to deliver a gene of choice to target cells/tissue. Viral vectors are derived from different viruses and as such are characterised by different features. These vectors play a fundamental role in molecular biology research and are applicable in the field of gene therapy and vaccine development.
GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 100+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of recombinant viral vector-based medicinal preparations.
Key players in recombinant viral vector-based medicinal preparations – a disruptive innovation in the pharmaceutical industry
‘Application diversity’ measures the number of different applications identified for each relevant patent and broadly splits companies into either ‘niche’ or ‘diversified’ innovators.
‘Geographic reach’ refers to the number of different countries each relevant patent is registered in and reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.
Patent volumes related to recombinant viral vector-based medicinal preparations
|Company||Total patents (2010 - 2021)||Premium intelligence on the world's largest companies|
|C. H. Boehringer Sohn||460||Unlock company profile|
|Merck & Co||284||Unlock company profile|
|Bavarian Nordic||271||Unlock company profile|
|Johnson & Johnson||246||Unlock company profile|
|GSK||216||Unlock company profile|
|Centre National de la Recherche Scientifique||136||Unlock company profile|
|Cevante Animale||119||Unlock company profile|
|Etubics||107||Unlock company profile|
|Pfizer||87||Unlock company profile|
|AlphaVax||83||Unlock company profile|
|Precigen||62||Unlock company profile|
|Sanofi||59||Unlock company profile|
|Otsuka Holdings||59||Unlock company profile|
|US Department of Health and Human Services||56||Unlock company profile|
|CareGroup||55||Unlock company profile|
|Compagnie Merieux Alliance||54||Unlock company profile|
|Nant Holdings Ip||46||Unlock company profile|
|Hookipa Pharma||44||Unlock company profile|
|Helmholtz Association of German Research Centres||41||Unlock company profile|
|Altimmune||38||Unlock company profile|
|PsiOxus Therapeutics||37||Unlock company profile|
|Theravectys||36||Unlock company profile|
|ViroNovative||36||Unlock company profile|
|ImmunityBio||35||Unlock company profile|
|Genelux||34||Unlock company profile|
|Erasmus MC||32||Unlock company profile|
|Vaxart||31||Unlock company profile|
|Spanish National Research Council||31||Unlock company profile|
|Emergent BioSolutions||31||Unlock company profile|
|Nestle||28||Unlock company profile|
|Takeda Pharmaceutical||27||Unlock company profile|
|International AIDS Vaccine Initiative||27||Unlock company profile|
|United States Of America||26||Unlock company profile|
|City of Hope||25||Unlock company profile|
|Utilities Service Alliance||23||Unlock company profile|
|Consejo Superior Investigacion||23||Unlock company profile|
|Nouscom||22||Unlock company profile|
|Zoetis||21||Unlock company profile|
|Gritstone Bio||21||Unlock company profile|
|Abbott Laboratories||21||Unlock company profile|
|AMVAC C.V.||21||Unlock company profile|
|Memorial Sloan Kettering Cancer Center||20||Unlock company profile|
|Panacea Biotec||20||Unlock company profile|
|Institut Pasteur||18||Unlock company profile|
|US Government||18||Unlock company profile|
|I'rom Group||16||Unlock company profile|
|American Gene Technologies International||16||Unlock company profile|
|U.S. Department of Defense||16||Unlock company profile|
|Intervet||15||Unlock company profile|
|National Resilience||15||Unlock company profile|
Source: GlobalData Patent Analytics
Merck is one of the leading patent filers in recombinant viral vector-based medicinal preparations. Merck is a biopharmaceutical company focused on the discovery, development, manufacturing and marketing of prescription medicines, biologic therapies, vaccines, and animal health products. V-184, Lassa fever vaccine, LV-305, and MV-ZIKA are some of the recombinant vector vaccines, which are in clinical stages of development by Merck.
In terms of application diversity, RegenxBio is the top company, followed by Iceni Pharmaceuticals and PsiOxus Therapeutics. By means of geographic reach, Redbiotec holds the top position. Replimune Group and Panacea Biotec are in second and third positions, respectively.
To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.